USFDA concludes inspection at Biocon Campus Site 1 facility of Biocon’s arm

01 Mar 2024 Evaluate

The U.S. Food and Drug Administration (USFDA) has concluded the inspection at Biocon’s subsidiary -- Biocon Biologics’ (BBL) Biocon Campus (Site 1) facility. USFDA had conducted an inspection at Biocon Biologics’ Biocon Campus (Site 1) facility between February 20-28, 2024.

At the conclusion of this inspection, the agency has issued Form 483s with 4 observations. The Company will submit a comprehensive Corrective and Preventive Action (CAPA) Plan to the U.S. FDA within the stipulated time and is committed to addressing these observations expeditiously. The outcome of this inspection at Site 1 does not impact the manufacturing and distribution of the Company’s commercial products in the US market.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

316.15 -4.65 (-1.45%)
31-Oct-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1849.05
Dr. Reddys Lab 1274.25
Cipla 1553.20
Lupin 2184.00
Zydus Lifesciences 1001.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.